Literature DB >> 6961972

Pharmacokinetics of low-dose methotrexate in children receiving maintenance therapy for acute lymphoblastic leukaemia.

C R Pinkerton, S G Welshman, J G Kelly, R G Shanks, J M Bridges.   

Abstract

Serum methotrexate (MTX) concentrations were measured by immunoassay in 28 children receiving maintenance therapy for acute lymphoblastic leukaemia. Patients were studied either after a single weekly dose or on the first day of a 5-day course of treatment. A standard dose (15 mg/m2) was given PO and/or IV. After PO dose the peak serum MTX concentration and its timing varied widely between cases and there was a significant positive correlation between the rate of serum concentration rise and the area under the concentration curve up to 4 h. The absorption rate constant showed a biphasic distribution and correlated less closely with early serum concentrations. After IV and PO administration drug disposition was triphasic with an initial rapid distribution phase, an intermediate phase, and a prolonged terminal elimination phase. The intermediate phase half-life was significantly longer after PO than after an IV dose. The MTX clearance rate was consistently lower than the glomerular filtration rate and there was no significant correlation between the two. The mean bioavailability (PO/IV) was 42%, but bioavailability was as low as 6% in some cases due to prolonged high serum concentrations after an IV dose, which was not seen with the equivalent PO dose.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6961972     DOI: 10.1007/BF00257235

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  15 in total

1.  Analysis of treatment in childhood leukaemia. II. Timing and the toxicity of combined 6-mercaptopurine and methotrexate maintenance therapy.

Authors:  I C MacLennan; H E Kay; M Festenstein; P G Smith
Journal:  Br J Haematol       Date:  1976-06       Impact factor: 6.998

2.  A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine.

Authors:  G J Schwartz; G B Haycock; C M Edelmann; A Spitzer
Journal:  Pediatrics       Date:  1976-08       Impact factor: 7.124

Review 3.  Clinical pharmacokinetics of methotrexate.

Authors:  D D Shen; D L Azarnoff
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

4.  The metabolic fate of tritiated methotrexate. II. Absorption and excretion in man.

Authors:  E S Henderson; R H Adamson; V T Oliverio
Journal:  Cancer Res       Date:  1965-08       Impact factor: 12.701

5.  Pharmacokinetics of methotrexate.

Authors:  D H Huffman; S H Wan; D L Azarnoff; B Hogstraten
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

6.  The characteristics of the membrane transport of amethopterin and the naturally occurring folates.

Authors:  I D Goldman
Journal:  Ann N Y Acad Sci       Date:  1971-11-30       Impact factor: 5.691

7.  Degradation and clearance of methotrexate in children with osteosarcoma receiving high-dose infusion.

Authors:  Y M Wang; P Y Kim; E Lantin; D C van Eys; M M Romsdahl; W W Sutow
Journal:  Med Pediatr Oncol       Date:  1978

8.  Some observations on the human pharmacology of methotrexate.

Authors:  A H Calvert; P K Bondy; K R Harrap
Journal:  Cancer Treat Rep       Date:  1977-12

9.  Absorption of methotrexate under standardized conditions in children with acute lymphoblastic leukaemia.

Authors:  C R Pinkerton; S G Welshman; S I Dempsey; J M Bridges; J F Glasgow
Journal:  Br J Cancer       Date:  1980-10       Impact factor: 7.640

10.  Development and application of a radioimmunoassay for methotrexate.

Authors:  G W Aherne; E M Piall; V Marks
Journal:  Br J Cancer       Date:  1977-11       Impact factor: 7.640

View more
  12 in total

1.  The bioavailability of oral intermediate-dose methotrexate. Effect of dose subdivision, formulation, and timing in the chemotherapy cycle.

Authors:  V J Harvey; M L Slevin; R C Woollard; A Johnston; M J Barnett; P F Wrigley; P Turner
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

2.  Pharmacokinetics of oral and intramuscular methotrexate in children with acute lymphoblastic leukaemia.

Authors:  A D Pearson; S Mills; H A Amineddine; D R Long; A W Craft; J M Chessells
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  Maintenance chemotherapy for childhood acute lymphoblastic leukemia: relation of bone-marrow and hepatotoxicity to the concentration of methotrexate in erythrocytes.

Authors:  K Schmiegelow; H Schrøder; M K Pulczynska; M Hejl
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 4.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of drugs used in juvenile arthritis.

Authors:  K J Skeith; F Jamali
Journal:  Clin Pharmacokinet       Date:  1991-08       Impact factor: 6.447

6.  Oral methotrexate is as effective as intramuscular in maintenance therapy of acute lymphoblastic leukaemia.

Authors:  J M Chessells; A D Leiper; K Tiedemann; R M Hardisty; S Richards
Journal:  Arch Dis Child       Date:  1987-02       Impact factor: 3.791

7.  An extended-release formulation of methotrexate for subcutaneous administration.

Authors:  A Bonetti; E Chatelut; S Kim
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

8.  Pharmacokinetics of erythrocyte methotrexate in children with acute lymphoblastic leukemia during maintenance treatment.

Authors:  H Schrøder; N Clausen; E Ostergaard; T Pressler
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

9.  Relative bioavailability of oral low dose methotrexate. A comparison of 2 different formulations.

Authors:  S D Fosså; K Tveit; O Börmer; A Moxnes; N P Jørgensen; H Orjaseter; D T Kristoffersen
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

10.  Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 1: methotrexate.

Authors:  Kayode Ogungbenro; Leon Aarons
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-03-21       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.